DMD Simcyp

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
QUICK SEARCH:   [advanced]


     

Drug Metabolism and Disposition Fast Forward
First published on May 30, 2008; DOI: 10.1124/dmd.108.021808

This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.108.021808v1
36/9/1753    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Prakash, C.
Right arrow Articles by Potchoiba, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Prakash, C.
Right arrow Articles by Potchoiba, M.


Received for publication April 8, 2008.
Revised May 28, 2008.
Accepted for publication May 29, 2008.

METABOLISM, DISTRIBUTION AND EXCRETION OF A NEXT GENERATION SELECTIVE ESTROGEN RECEPTOR MODULATOR, LASOFOXIFENE, IN RATS AND MONKEYS

Chandra Prakash 1*, Kim Johnson 1, Clinton Schroeder 1, Michael Potchoiba 1

1 Pfizer

* Address correspondence to: E-mail: chandra.prakash{at}pfizer.com

Abstract

Disposition of lasofoxifene (LAS) was investigated in rats and monkeys after oral administration of a single oral dose of [14C]LAS. Total mean recoveries of the radiocarbon were 96.7 and 94.3% from rats and monkeys, respectively. The major route of excretion in both species was the feces and based on a separate study in the bile duct-cannulated rat, this likely reflects excretion in bile rather than incomplete absorption. Whole-body autoradioluminography suggested that [14C]LAS radioequivalents distributed rapidly in the rat with most tissues achieving maximal concentrations at 1 h. Half-life of radioactivity was longest in the uvea (124 h) and shortest in the spleen (~ 3 h). LAS was extensively metabolized in both rats and monkeys since no unchanged drug was detected in urine and/or bile. Based on AUC(0-24) values, >78% of the circulating radioactivity was due to the metabolites. A total of 22 metabolites were tentatively identified by LC-MS/MS. Based on the structures of the metabolites, six metabolic pathways of LAS were identified: hydroxylation at the tetraline ring, hydroxylation at the aromatic ring attached to tetraline, methylation of the catechol intermediates by catechol-O-methyl transferase, oxidation at the pyrrolidine ring and direct conjugation with glucuronic acid and sulfuric acid. LAS and its glucuronide conjugate (M7) were the major circulating drug related moieties in both rats and monkeys. However, there were notable species-related qualitative and quantitative differences in the metabolic profiles. The catechol (M21) and its sulfate conjugate (M10) were observed only in monkeys while the glucuronide conjugate of the methylated catechol (M8), and hydroxy-LAS (M9) were detected only in rats.


Key words: drug disposition, mass spectrometry, metabolite identification, phase II drug metabolism, sulfate conjugation




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics.